GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » Interest Income

NanoString Technologies (NanoString Technologies) Interest Income : $5.2 Mil (TTM As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. NanoString Technologies's interest income for the three months ended in Sep. 2023 was $1.4 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2023 was $5.2 Mil.


NanoString Technologies Interest Income Historical Data

The historical data trend for NanoString Technologies's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies Interest Income Chart

NanoString Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 2.82 1.74 0.65 2.41

NanoString Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 1.08 1.29 1.53 1.36

NanoString Technologies Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NanoString Technologies (NanoString Technologies) Business Description

Traded in Other Exchanges
Address
530 Fairview Avenue North, Seattle, WA, USA, 98109
NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.
Executives
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey officer: Chief Financial Officer 1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray director, officer: President and CEO 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr director, 10 percent owner 11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem officer: SVP, Research & Development 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace officer: Chief Commercial Officer C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown officer: SVP, Sales & Marketing 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Janet George director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109